Click Here to Read More

A recently published study in the British Journal of Nursing, authored by Angela Hastings and Andrew Barton, demonstrates StatSeal efficacy for managing PICC exit site bleeding and improving patient outcomes. The purpose of the trial “was to evaluate the efficacy and safety of StatSeal for haemostasis following PICC line insertion. The trial was conducted on adult inpatients requiring a PICC or outpatients requiring a PICC for chemotherapy or home IV antibiotics.” The primary endpoint was dressings that lasted 7 days. Of the StatSeal dressings, 99% lasted 7 days, whereas only 7% of the dressings without StatSeal lasted 7 days. The conclusion indicated “Using StatSeal improved patient outcomes and reduced the number of dressing changes required in a 7-day period, saving time and money. StatSeal is a reliable, valuable product for the management and control of vascular access catheter exit site bleeding.” Read the full article here: https://www.biolife.com/news/hastings-2024/

BILLERICA, Mass.--(BUSINESS WIRE )--Access Vascular, Inc. (AVI), a medical device company dedicated to reducing and eliminating common and costly vascular access complications with its novel MIMIX® catheter material, announced today that it is preparing to submit its HydroGUIDE™ catheter placement technology for U.S. Food & Drug Administration (FDA) clearance.

Click Here to Read Full Press Release